STOCK TITAN

Monogram Technologies Inc. - MGRM STOCK NEWS

Welcome to our dedicated page for Monogram Technologies news (Ticker: MGRM), a resource for investors and traders seeking the latest updates and insights on Monogram Technologies stock.

Monogram Technologies Inc. Common Stock (NASDAQ: MGRM) is a forward-thinking medical technology company specializing in the development of AI-driven robotic systems and patient-specific orthopedic implants. Formerly known as Monogram Orthopaedics Inc., the company aims to revolutionize reconstructive joint procedures through the integration of 3D printing, advanced machine vision, and next-generation robotics.

Monogram Technologies' flagship product, the mBŏs precision robotic surgical system, is designed to autonomously perform high-precision insertions of FDA-cleared press-fit implants. The system integrates automated digital image analysis algorithms and machine learning to deliver scalable, patient-specific load-bearing joint replacements. Their innovations are set to transform knee replacement surgeries by offering minimally invasive procedures that promise better-fitting and bone-sparing implants.

The company’s current and upcoming product lines include robotic surgical equipment, related software, orthopedic implants, tissue ablation tools, and navigation consumables. They are also in the verification and validation phase for their robotic products, aiming for a 510(k) submission to the FDA in the second half of 2024.

Recently, Monogram achieved significant milestones, including the delivery of their first surgical robot to a major global distributor, marking their entry into commercial revenues. The company's mBŏs robot addresses a major gap in the $19.4 billion knee replacement market, which still relies heavily on manual procedures for approximately 88% of surgeries.

Monogram Technologies continues to advance its commercialization roadmap while exploring new applications for its technology. Their mVision navigation system, aimed at eliminating cart-based tracking and minimizing surgical time, represents another leap forward in orthopedic robotics. As part of their growth strategy, Monogram is also actively seeking partnerships with independent distributors to further expand its market reach.

Visit www.monogramorthopedics.com for more information and the latest updates on their developments.

Rhea-AI Summary

Monogram Orthopaedics Inc. provided an update regarding its mBôs surgical system regulatory path after a meeting with the FDA, revealing accelerated 510(k) submission plans for early second half of 2024. The FDA feedback on the Q1 2023 submission was positive, supporting a least burdensome approach to clinical data acquisition. Management aims to conduct an OUS clinical trial, estimating costs at $1.5M, to support post-launch marketing. Monogram anticipates leveraging OUS clinical data and an accommodating FDA stance towards it to expedite technology pipeline development, including mVision tracking solution. Verification and Validation testing nearing completion in Q2 2024, with a 510(k) submission expected in late 2024. The company's modified mBôs system design aims to minimize the risk of FDA clinical data requests. Various tests and validations are progressing well, with strategic engagements with external partners, including MCRA, aiding in regulatory strategy execution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
none
-
Rhea-AI Summary
Monogram Orthopaedics Inc. announces collaboration with NVIDIA Inception program to accelerate the development and commercialization of its mBôs robotic surgical equipment and related orthopedic products. The partnership aims to provide technical resources, go-to-market support, and access to investors and industry experts for Monogram's innovative orthopedic robotics technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
79.3%
Tags
none
-
Rhea-AI Summary
Monogram Orthopaedics Inc. (NASDAQ:MGRM) to host a business update conference call to discuss fiscal year 2023 results and 2024 milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.11%
Tags
conferences
Rhea-AI Summary
Monogram Orthopaedics Inc. (MGRM) reports financial results for Q4 2023, plans 510(k) FDA submission in 2024, introduces mVision technology, and delivers first mBôs surgical robot to global distributor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
-
Rhea-AI Summary
Monogram Orthopaedics Inc. (NASDAQ:MGRM) hosted a discussion on its mBôs commercial robot and mVision technologies with a surgeon panel. The company plans to integrate mVision technology into the mBôs surgical robotic system. Ben Sexson, CEO, will present at the 2024 Canaccord Genuity Musculoskeletal Conference and AAOS Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences
-
Rhea-AI Summary
Monogram Orthopaedics Inc. (MGRM) is set to present at the Canaccord Genuity 2024 Musculoskeletal Conference in San Francisco. CEO Ben Sexson and CFO Noel Knape will host a presentation and participate in one-on-one meetings. The event will take place on February 12, 2024, at 4:30 p.m. Pacific time. For more information, visit the webcast link provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
Rhea-AI Summary
Monogram Orthopaedics Inc. (NASDAQ:MGRM) has postponed the live stream product demonstration of its commercial robot due to management's international travel schedules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
none
-
Rhea-AI Summary
Monogram Orthopaedics Inc. (NASDAQ:MGRM) will host a live stream product demonstration of its commercial robot, the mBôs Surgical Robot, on December 14, 2023, at 11:00 a.m. Eastern Time. The demo follows the recent delivery of the first surgical robot to a global distributor. The company aims to provide a robotic solution with favorable economics for hospitals and uncompromised performance for patients and surgeons.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
conferences
-
Rhea-AI Summary
Monogram Orthopaedics Inc. (MGRM) achieves a significant revenue milestone by delivering its first surgical robot to a major global distributor. The company's CEO, Ben Sexson, emphasizes the validation of their technology and the pivotal nature of this achievement. Monogram's focus on reconstructive joint procedures and surgical robotics aims to improve the standard of care for orthopedic patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.69%
Tags
none
Rhea-AI Summary
Monogram Orthopaedics announces filing of 8-K with updated presentation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none

FAQ

What is the current stock price of Monogram Technologies (MGRM)?

The current stock price of Monogram Technologies (MGRM) is $2.58 as of December 20, 2024.

What is the market cap of Monogram Technologies (MGRM)?

The market cap of Monogram Technologies (MGRM) is approximately 84.8M.

What does Monogram Technologies Inc. do?

Monogram Technologies Inc. develops AI-driven robotic systems and patient-specific orthopedic implants to revolutionize reconstructive joint procedures.

What is the mBŏs precision robotic surgical system?

The mBŏs system is a robotic surgical assistant designed to autonomously execute high-precision insertion of FDA-cleared press-fit implants.

What recent milestones has Monogram Technologies achieved?

Monogram recently delivered its first surgical robot to a major global distributor, marking a key revenue milestone and entry into commercial markets.

When does Monogram Technologies plan to submit their 510(k) for FDA clearance?

Monogram plans to submit their 510(k) for FDA clearance in the second half of 2024.

What is mVision technology?

mVision is a next-generation navigation system designed to eliminate cart-based tracking, reduce surgical time, and minimize the surgical footprint in the OR.

What markets is Monogram Technologies targeting?

Monogram targets the orthopedic joint replacement market, especially knee replacements, aiming to improve surgical outcomes and patient-specific implant fitting.

Is Monogram Technologies seeking partnerships?

Yes, Monogram is actively seeking partnerships with independent distributors to expand its market reach.

What makes Monogram Technologies' products unique?

Monogram's products are unique due to their integration of AI, 3D printing, and robotic precision, offering scalable and patient-specific solutions for orthopedic implants.

How is Monogram Technologies funded?

Monogram Technologies is publicly traded on NASDAQ under the symbol MGRM and has secured sufficient funding to proceed with their planned FDA submissions and further product development.

Where can I learn more about Monogram Technologies?

For more information, visit their official website at www.monogramorthopedics.com.

Monogram Technologies Inc.

Nasdaq:MGRM

MGRM Rankings

MGRM Stock Data

84.75M
22.28M
34.22%
3.85%
0.81%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
BROOKLYN